NRXPNasdaq

NRX Pharmaceuticals Inc.

Healthcare·Neurology·Commercial·Wilmington, DE, United States
NeurologyInfectious Disease

NRX Pharmaceuticals Inc. (NRXP): 4 pipeline candidates · ~5 mo cash runway. Updated within the last hour.

7.0/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway1.3

4.8 months

Financial Health10.0

D/E -1.86 · 0% dilution

Pipeline Maturity9.5

Lead: BLA Filed

Pipeline Breadth7.2

4 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for NRX Pharmaceuticals Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$170.3M

Cash

$6.7M

Quarterly Burn

$4.3M

Runway

4.8 mo

Revenue

$1.1M

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Nov 2026
Today~7 mo out
Catalyst within runway

Pipeline (4 candidates)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

32

Total value held

$9.5M

HolderSharesValue
vanguard capital management llc2,320,368$4.9M
advisorshares investments llc420,467$896K
commonwealth equity services, llc397,431$847K
geode capital management, llc310,112$661K
jane street group, llc180,652$385K
vanguard fiduciary trust co169,580$361K
susquehanna international group, llp102,200$218K
blackrock, inc.98,995$211K
state street corp86,984$185K
xtx topco ltd78,733$168K

Showing top 10 of 32 institutional holders of NRX Pharmaceuticals Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

·1 FDA decision·CEO: Dr. Jonathan C. Javitt M.D., M.P.H.

Frequently asked questions

How many drug candidates are in NRX Pharmaceuticals Inc.'s pipeline?

NRX Pharmaceuticals Inc. (NRXP) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is NRX Pharmaceuticals Inc.'s lead drug candidate?

NRX Pharmaceuticals Inc.'s most advanced tracked candidate is htx-100 (Preclinical) for Suicidal depression, PTSD, and other serious Central Nervous System (CNS) disorders.

What is NRX Pharmaceuticals Inc.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, NRX Pharmaceuticals Inc. has approximately 4.8 months of cash runway.

What is NRX Pharmaceuticals Inc.'s market capitalization?

NRX Pharmaceuticals Inc.'s market capitalization is approximately $170.3M.

Who is the CEO of NRX Pharmaceuticals Inc.?

Dr. Jonathan C. Javitt M.D., M.P.H. is the chief executive officer of NRX Pharmaceuticals Inc. (NRXP).

Get the full picture on NRX Pharmaceuticals Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.